Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The 505(b)(2) pathway, established by the USFDA, enables faster approval of new drug applications (NDAs) by allowing partial reliance on existing clinical data. This regulatory mechanism fosters innovation by encouraging new formulations, combinations, and delivery systems, accelerating the availability of advanced therapeutics.
Objective: This study provides a comprehensive analysis of 505(b)(2) NDA approvals from 2019 to 2023, with an emphasis on trends, major players, therapeutic targets, and dosage form diversity. Furthermore, the impact of regulatory exclusivity strategies on market dynamics and drug pricing is explored.
Methods: Approval data was gathered from the USFDA database and further classified by reformulation type, therapeutic area, primary players, and dosage form. The study also analyzed the therapeutic equivalence codes and the influence of non-patent exclusivity strategies on market competition to identify trends and the prevalence of product types across therapeutic categories.
Results: Our findings reveal a strong presence of reformulations, with new dosage forms (Type 3) and new formulations or other differences (Type 5) accounting for a substantial portion of approvals. Cancer (16.7%), CNS disorders (16.2%), and anti-infective treatments emerged as key therapeutic areas. Teva Pharmaceuticals USA Inc. was the leading entity by approval count. Parenteral dosage forms dominated at 40.3%, followed by tablets at 20.6%. Exclusivity strategies, notably three year's new clinical investigation exclusivity, impacted drug pricing and competitive positioning.
Conclusion: The 505(b)(2) pathway proves instrumental in advancing pharmaceutical innovation and expediting access to therapies targeting unmet needs. These insights offer value for regulatory professionals, drug developers, and policymakers in optimizing development and market strategies to enhance drug accessibility. Companies must remain vigilant and proactive in anticipating potential blocking exclusivities to secure successful approvals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43441-025-00775-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Breast Reconstruction Strategies Using Exclusive Lipofilling or Prosthesis After Total Mastectomy for Breast Cancer: Satisfaction and Morbidity After More Than 2 Years.
Aesthet Surg J
September 2025
Department of Gynecological and Breast Surgery and Oncology, Assistance Publique des Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, Paris, France.
Background: Total mastectomy for breast cancer is an impactful procedure, and breast reconstruction plays a crucial role for women diagnosed with the disease.
Objectives: The objective of our study is to compare satisfaction, morbidity, and timelines of two breast reconstruction techniques after breast cancer: breast prosthesis and exclusive lipofilling.
Methods: This is a comparative, retrospective, unicentric study on patients who underwent total mastectomy between May 2014 and May 2020.
A vegetarian diet improves hepatic steatosis in MASLD patients through weight loss: a randomized controlled trial in China.
Food Funct
September 2025
School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
: The therapeutic potential of vegetarian diets in metabolic dysfunction-associated steatotic liver disease (MASLD) remains understudied in Asian populations. This randomized controlled trial aimed to evaluate the effects of a culturally adapted 6-month lacto-ovo-vegetarian diet (LOV-D) on hepatic steatosis and cardiometabolic risk factors through weight loss. : In this randomized trial, 220 Chinese adults with MASLD were assigned to LOV-D ( = 110) or an omnivore diet ( = 110) for 6 months.
View Article and Find Full Text PDFDecoding the Interactions Between Antibiotics and Microplastics- Chemistry, Environmental Impacts, and Mitigation Approaches- A State-of-the-Art Review.
Environ Res
September 2025
Department of Chemical Engineering, National Institute of Technology Durgapur, Durgapur-713209, India. Electronic address:
The coexistence of antibiotics (AB) and microplastics (MP) in the environment has led to the formation of AB-MP complexes, posing several ecological and public health challenges. This review explores the mechanisms driving AB adsorption onto MPs, including diverse interactions (hydrophobic interactions, hydrogen bonding, π-π stacking, and ionic exchange) and their role in maintaining the persistence and mobility of the complexes. These complexes have been reported to serve as reservoirs/vectors for antimicrobial resistance (AMR), disrupt microbial communities, and enhance the bioavailability of ABs, thus posing various threats affecting biodiversity health and ecosystem stability.
View Article and Find Full Text PDFEfficacy of Virtual Reality in Managing Pain for Patients in Palliative Care: A Systematic Review and Meta-Analysis.
J Pain Symptom Manage
September 2025
School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.
Background: Pain management in palliative care, especially among cancer patients, remains a critical challenge that significantly affects patient quality of life. Virtual Reality (VR) has emerged as a promising non-pharmacological intervention that could revolutionize pain management strategies in this vulnerable population. This systematic review and meta-analysis evaluate the effectiveness of VR interventions, focusing exclusively on randomized controlled trials to provide a comprehensive assessment of VR as a therapeutic tool.
View Article and Find Full Text PDFRemodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity.
J Pharmacol Exp Ther
August 2025
Animal Cancer Care and Research Program, University of Minnesota, St Paul, Minnesota; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Center for Immunology
We evaluated the antitumor effects of remodeling the MC17 mouse sarcoma microenvironment (SME) by targeting urokinase-type plasminogen activator receptor (uPAR)- and epidermal growth factor receptor (EGFR)-expressing cells. Specifically, we used eBAT (a bispecific ligand-targeted toxin directed to EGFR and uPAR), and its mouse counterpart, meBAT, to ablate uPAR- and/or EGFR-expressing cells. We chose the MC17 model because the cells are resistant to eBAT, allowing us to exclusively evaluate the role of uPAR- and EGFR-expressing cells in the SME.
View Article and Find Full Text PDF